Precision dermatology 2050: AI-driven personalized monitoring and individualized treatment

By 2050, advances in artificial intelligence (AI), Internet of Medical Things (IoMT) and teledermatology are predicted to fundamentally transform the diagnosis and management of chronic inflammatory skin conditions. This white paper examines the anticipated patient journey in 2050, emphasizing personalized, technology-driven healthcare approaches that integrate innovations in discovery, diagnosis, monitoring, therapy and preventive care across global healthcare settings. The patient journey in affluent countries is expected to be characterized by a shift towards at-home self-assessments, teledermatology, proactive disease management and comprehensive health data integration. A personalized, conversational AI assistant supports both patient and doctor as a Digital Companion (DC). The system is continuously calibrated to enhance treatment effectiveness. Monitoring is facilitated by sensors, common Internet of Things (IoT) and specialized IoMT devices that detect anomalies and trigger alerts. The system learns to predict flare-ups based on trigger exposure and medication effectiveness, leading to individual recommendations for preventive measures. In resource-limited settings, adapted teledermatology platforms will leverage simplified diagnostic tools and mobile technologies to significantly expand access to dermatologic expertise. Global data repositories on dermatological conditions across diverse skin types and ethnicities will enhance diagnostic accuracy for all populations. Advances in point-of-care diagnostics will enable molecular and genetic skin analysis in real time, facilitating truly personalized treatment regimens. The dermatologist's role will evolve towards managing complex cases, interpreting AI-generated insights and overseeing treatment algorithms while AI systems handle routine diagnoses and monitoring. Regulatory frameworks will evolve to address the ethical implications of autonomous diagnostic systems and cross-border virtual care delivery, while new economic models will emerge to support equitable access to these technologies across different healthcare systems. This transformation will not only improve clinical outcomes but also enhance quality of life through earlier intervention, reduced disease burden and more patient-centred care models globally.